Although the CD5 (T1) antigen was initially described as a pan-T cell membrane glycoprotein, we report that 14 of 40 normal individuals were found to have 5% or greater of their blood mononuclear cells characterized as CD3 (T3)+ but CDSby dual immunofluorescence flow cytometry. These cells expressed normal quantities of surface CD3 and CD2 but low levels of CD7, were CD8' and CD4-, and CD16-. In order to determine whether cells of this phenotype were functional, six CD5-cytolytic T lymphocyte (CTL) clones isolated from normal individuals were studied. The CDS-CTL clones all demonstrated normal cytolytic activity against appropriate target cells. Monoclonal antibodies (MAbs) directed against CD3, CD8, CD2, and lymphocyte function-associated antigen 3, but not against CD5, inhibited cytolytic activity. Changes in intracellular calcium (ICa2+I,) in response to anti-CD5 and anti-CD3 MAbs were measured. Stimulation by anti-CD5 MAb alone did not give rise to a change in ICa2+I. However, under conditions of limiting concentrations of anti-CD3 MAb, preincubation of normal CD5', but not CD5-, clones with anti-CD5 MAb led to a dramatic enhancement in the ability of anti-CD3
Introduction
The CD5 molecule is a lymphocyte cell surface glycoprotein with a relative molecular mass of67,000 daltons, thought to be expressed on all mature thymocytes, peripheral T cells, and a subset of B cells (1) (2) (3) (4) (5) (6) (7) . While the functional role of the molecule is unknown, monoclonal antibodies (MAbs) directed against the CD5 antigen augment T-cell proliferative responses to alloantigens and to mitogens, and this proliferation is associated with increased interleukin 2 (IL-2) production and IL-2 receptor expression (8) (9) (10) . Anti-CD5 MAb has also been shown to enhance T cell help for B-cell immunoglobulin production (1 1). These data suggest that the molecule may function to regulate T cell responses.
formed B-cell line JY (HLA-A2; B7; Dr4, 6; DQl, 3; DP2, 4), 1 X 105 cells/ml. The bulk culture was restimulated every 7-10 d with irradiated JY cells. The cultures were maintained in 2-ml wells (Linbro, McLean, VA) in culture medium for the first 3 wk and then supplemented with 10% human-conditioned medium. Periodically after the third stimulation, cells were cloned by limiting dilution in 96-well round-bottom microtiter plates (Linbro) with irradiated JY cells, 2 X 104 cells per well, as a feeder layer. Cells were serially diluted to a final calculated concentration of 0.1 cell per well, and later subcloned at 0.1 cell per well to ensure clonality. The T cell clones were maintained in culture medium containing 10% IL-2-containing humanconditioned medium, and restimulated every 7 d with irradiated JY cells. The antigen specificity of each clone was established using cytotoxicity of a panel of HLA-typed EBV-transformed B cell lines and by the ability to inhibit such cytotoxicity by appropriate MAb. The phenotype of each clone was established using dual parameter fluorescence-activated cell sorter (FACS) analysis.
Monoclonal antibodies. Four anti-CD5 MAbs were used in this study: anti-Leu I (IgG2a), OK-CLL (IgGI) (Ortho Diagnostic Systems, Inc., Raritan, NJ), OKTI (IgGI) (American Type Culture Collection, Bethesda, MD), and TI (IgGI) (Coulter, Hialeah, FL) MAb. OKT3 (IgG2a), W6/32 (IgG2a), OKT8 (IgGI), and MMA (IgG2a) MAbs were purchased from the American Type Culture Collection, subcloned, and grown as ascitic fluid ofpristane-primed BALB/c mice.
MAbs to CDI la (lymphocyte function-associated antigen [LFAJ-l), CD2 (TS2/18), LFA-3 (TS2/9), and HLA-DR (LB3. 1) have been previously described (16-18). The MAbs 4F2 (19) , the generous gift ofDr. J. Strominger, Boston, MA, and MMA (20) were used at a 1:150 dilution ofascitic fluid. Commercial MAbs were also used: anti-Leu 2 (CD8), anti-Leu 3 (CD4), anti-Leu 4 (CD3), anti-Leu 5 (CD2), antiLeu 6 (CD1), anti-Leu 7, anti-Leu 9 (CD7), anti-Leu II (CD16), 45 -60 min at 370C on a shaker platform. The Indo-l-loaded cells were washed twice, resuspended in Hanks' balanced salt solution (M. A. Bioproducts) containing 2% heat-inactivated FBS, and stored in the dark at 370C until analysis. Cytoplasmic calcium was monitored by flow cytometry using a FACS I analyzer as described (22) . Briefly, Indo-1 fluorescence was excited by a mercury arc lamp directed through a 353-nm band-pass filter. A 480-nm band-pass filter (Ditric Optics, Inc., Hudson, MA) and a 405-nm line filter (Corion Corp., Holliston, MA) were used to collect fluorescence emission after separation with a 450-nm dichroic filter (Corion Corp.). The ratio of fluorescence emissions, 405 nm/480 nm, reflects the relative intracellular calcium concentration [Ca2+]i (23) , and is expressed as contour histograms plotted against the volume of the cells analyzed, using a Consort 30 computer (Becton-Dickinson). An increase in the ratio of fluorescence emission greater than 2 SD above baseline mean fluorescence ratio was considered a significant rise in [Ca'+Ji. Temperature was maintained at 370C.
Results
A small population ofnormal PBL lack surface expression of CD5. The CD5 molecule was initially identified as a "pan-T cell marker," expressed early in thymic ontogeny and on all peripheral T cells (1, 4, 5) . Dual immunofluorescence FACS analysis of peripheral blood mononuclear cells from 40 normal volunteers was performed, and the percentage of lymphocytes of CD3' CD5-phenotype was found to vary from 0% to 27% (5±6%; mean±SD) in these 40 individuals. 14 of the 40 normal donors had greater than or equal to 5% CD3+ CD5-cells. A panel of representative fluorescence histograms is shown in Fig. 1 . In the majority of individuals, CD3 and CD5 are coexpressed and < 1% of cells are CD3+ CD5- (Fig. 1 A) . However, other individuals (14 of 40) show a significant population of such cells. One representative individual with -8% circulating CD3+ CD5-cells is shown in Fig. 1 B. By dual immunofluorescence, the expression of CD5 in the normal PBMC populations varies from negative to brightly positive ( Fig. 1, B and D). The CD3+ CD5-population appears to occur predominantly in the CD8 (T8, Leu 2)+ subset ( Fig. 1  D) . Thus, as shown in Fig. 1 C, virtually all CD3+ CD4 (T4, Leu 3)+ cells are CD5'. The CD8+ cells are all CD3+ (Fig. 1 F) but only -50% are CD5+ (Fig. 1 D) . The CD8+population of cells do not express the cell surface markers CD16 (Leu 1 1) ( Fig. 1 E) nor CDl 1 (Leu 15, C3bi receptor, data not shown), and, therefore, do not demonstrate the phenotype characteristic of natural killer cells. The CD3+ CD5-cells were also found to be uniformly CD2 (TI 1, Leu 5, the sheep red blood cell receptor) positive, but show weak expression of CD7 (Leu 9) (data not shown). Expression of Leu 7 on these cells was highly variable but generally < 20% of the CD3+ CD5-cells expressed this antigen. There was no correlation between frequency of CD3+ CD5-cells and the total number of circulating cells expressing the natural killer cell marker CD 16, total CD3+ cells, or the number of circulating B cells as defined by
CDl9 (Leu 12).
To determine the phenotypic stability of the CD3+ CD5-population of cells in a given normal individual, seven healthy donors were studied on two to seven occasions over a 2-yr Human CDS-Cytolytic T Cells 1391 Anti -CD8
period. Serial analysis of all seven individuals demonstrated that the percentage ofCD31 CD5-cells fluctuated significantly over time, from < 2% to 7-22% of peripheral blood lymphocytes. All seven donors had at least one occasion in which the number of CD3' CD5-cells was < 2%, and, similarly, at least one occasion in which the number was > 5%. The percentage of T cells of CD31 CDS-phenotype is increased by in vitro allostimulation, a phenotype associated with increased lytic capacity. We examined whether the number of CD3' CD5-cells could be altered by in vitro allogeneic stimulation. PBMC from three donors were therefore stimulated with the allogeneic human EBV-transformed B cell line, JY, which had been previously irradiated. The phenotype of the cultures was examined. The proportion of CD3+ CD5-cells increased from 6% to 11%, from 7% to 22%, and from 14% to 22% from day 0 to day 6 for the three donors. Stimulation of PBMC with concanavalin A similarly increased the percentage ofCD3+ CD5-cells to approximately twice baseline levels (not shown). To determine if the CD3+ CD5-cells were capable of lysing the target cell JY, PBMC on day 0 were treated with anti-CD5 MAb and complement to lyse contaminating CD5+ cells. Cytofluorometric analysis revealed that the unlysed PBMC were 49% CD3+ and 16% CD3+ CD5-cells. After depletion with antibody and complement, < 1% of cells were CD5+ (T I') by indirect immunofluorescence. Both the bulk population and the CD3+ CD5-cultures were stimulated with JY, grown in human conditioned medium, and tested for cytolysis (Fig. 2) . At equal ratios of effector to target cells, the cytolytic capacity of the CD3+ CD5-cells was proportionately greater than the bulk population, reflecting the enrichment for CD8+ cells. Proliferation, assessed on day 6 by [3H]thymidine incorporation, of the two cultures was identical (not shown). Similarly, if cells were first stimulated with irradiated JY, and prior to assay on day 6, an aliquot was treated with anti-CD5 MAb plus complement, the CD3+ CD5-population lysed the target cells at proportionately greater efficiency than the bulk population. Again, proliferation of both populations was equivalent. Functional CTL clones, generated from normal individuals, may be CD5-. To study the function and phenotypic stability of the CD3+ CD5-cells which comprise < 5% of the total T cell population, we attempted to isolate these cells by cloning. In the bulk population, the CD3+ CD5-cells expressed the CD8 antigen, a marker which has been associated with cytolytic function (24-27), and we had found the bulk CD3+ CD5-population capable of cytolysis. Our strategy, therefore, to isolate CD5-clones was to screen for cytolytic activity. Clones were derived by limiting dilution from longterm alloantigen-stimulated bulk cultures from normal individuals and screened for CTL activity. Clones were phenotyped by both dual-and single-parameter immunofluores- 
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cence. In addition to CD5' clones, six CD5-clones were isolated. The phenotype of a representative CD5-clone is shown in Fig. 3 (29) . Recently, anti-CD5 MAb has also been shown to increase [Ca2]i in PBMC (30) . We therefore sought to investigate whether anti-CD5 MAb would augment the influx of [Ca2+]i induced by anti-CD3 MAb on CD5 and CD5-clones. CD5' CTL clones were incubated with the calciumsensitive fluorophore, Indo-1 (Fig. 4 A) (Fig. 4 B) . However, preincubation ofthese cells with anti-Leu 1 MAb (Fig. 4 C) (Fig. 4, D-F) . Thus the lack of expression of CD5 on CD5-clones by indirect immunofluorescence correlated with the functional loss of the calcium influx observed in response to anti-CD3 MAb.
CD3' CDS-clones exhibit normal cytolytic activity. The CD5-clones did not respond to anti-CD5 MAb. We therefore investigated whether these clones exhibited normal CTL activity. Specificity of cytolysis was determined using a panel of HLA-typed target cells and by inhibition ofcytolysis by monoclonal antibody blocking. Detailed analysis (Table I) lysed target cells expressing appropriate major histocompatibility complex (MHC) class I antigens and one of six clones lysed target cells expressing appropriate MHC class II antigens. The surface expression of CD3, CD2, and CD8 (Fig. 3) and LFA-l (not shown) was comparable to CD5' CTL clones.
MAb inhibition of cytolytic activity of two MHC class I-specific CD5-clones is shown in Table II . The lack of expression of the CD5 antigen did not appear to affect their lytic activity. Moreover, incubation ofthe clones with anti-CD3, anti-CD2, anti-LFA-3, and anti-CD8 MAb inhibited cytotoxicity, as has been observed for CD5' cytolytic clones (17, 26, 27, 32, 33 (34) (35) (36) (37) . We undertook a phenotypic and functional evaluation of CD5-cytolytic T cell clones generated by limiting dilution. (38) . We determined whether the small population of CD3+ CD5-cells were functionally competent. Primary alloreactive CD3+ CD5-demonstrated cytolytic activity. CD5-T cell clones isolated here, selected for lytic ability, were able to kill target cells efficiently. Cytolysis could be inhibited by monoclonal antibodies directed against the recognized MHC alloantigen, and by MAbs to CD3, CD8, CD2, and LFA-3, suggesting that triggering of lysis through the CD3 molecule and the utilization of accessory molecules was normal for CD5-clones.
The precise biological role of CD5 remains to be elucidated. The molecular mechanism by which anti-CD5 MAb binding to its ligand augments proliferative responses (6-10, 37) is unknown. Anti-CD5 MAb have been shown to provide the necessary second signal for activation of purified T cells stimulated with solid-phase bound anti-CD3 MAb (9) . Anti-CD5 MAb was shown here to enhance the anti-CD3 MAb-induced rise in intracellular concentration of calcium, an early signal in T cell activation in the T cell clones generated, as has been observed for PBMC (30) . The increase in sensitivity of the T cell population to limiting concentrations of anti-CD3 MAb may reflect a direct effect of anti-CD5 MAb on the calcium channel, or upon a distinct intracellular second messenger which, in turn, modulates the change in intracellular calcium stimulated by anti-CD3 MAb. Some (10, 30) (43, 44) . The functional analysis and growth requirements of these cells has not yet been reported.
Antibodies directed against the CD5 molecule have been used therapeutically in a variety ofsettings. In vivo administra-tion ofanti-CD5 MAb has been used to treat lymphoproliferative disorders (45, 46) . In bone marrow transplantation, anti-CD5 MAbs have been used singly (47, 48) 
